Actavis sells infrastructure to India's Aruobindo

Share this article:

Generics firm Actavis announced Friday that it was selling its pharmaceutical commercial infrastructure in France, Italy, Spain, Portugal, Belgium, Germany and the Netherlands, including products, marketing authorizations and dossier license rights to India's Aurobindo Pharma, which has been on a path of expanding its European footprint.

Friday's announcement follows Bloomberg's report that Actavis is looking to extricate itself from China. CEO Paul Bisaro told Bloomberg at the JP Morgan Healthcare conference that China's business climate is too difficult to continue to operate in. “It wasn't worth the aggravation, the frustration or the concern.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.